Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III regorafenib versus placebo in previously treated advanced GIST
2009-017957-37Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastrointestinal stromal tumor (GIST) comparing Regorafenib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Oct 2010; status: completed.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2009-017957-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017957-37.